Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics.
For the first quarter ended 30th June 2009, on a consolidated basis, the company registered a total operating income of Rs 852.8 crore, up 25% on a YoY. Formulation sales were up 62% at Rs.469 crore and this comprised 57% of its gross sales. Operating Profit before Forex was at Rs.195.7 crore, up by 71%. PAT after forex was at Rs 166.6 crore as against Rs.16.4 crore in Q1FY09. However, the PAT before Forex was at Rs.109 crore, up 55%.
During the quarter, the company repurchased and cancelled FCCBs of face value of USD 1.8 million. In Q1 FY 2009-10, it had 8 ANDA filings in USA, taking the total cumulative filings to155. It also had 13 Dossier filings in Europe in Q1 FY 2009-10 , taking the total cumulative filings to 677.
In August, the company acquired Hyderabad-based Trident Life Sciences for about Rs.134 crore. It will fund the deal through internal cash flow and will repay the debt on Trident Life Sciences' books in the next six to nine months. This acquisition will give Aurobindo an opportunity to enter the injectables business as Trident is building a liquid injectables facility in Medak, Hyderabad, scheduled to go on stream in April 2011.
Since the last few days, Aurobindo has acquired quite a few approvals for its drugs from USFDA as well as Switzerland. And that is precisely why the stock price has remained up and is expected to remain firm in the coming days too. A strong company, it’s a long term stock for portfolio building.
For the first quarter ended 30th June 2009, on a consolidated basis, the company registered a total operating income of Rs 852.8 crore, up 25% on a YoY. Formulation sales were up 62% at Rs.469 crore and this comprised 57% of its gross sales. Operating Profit before Forex was at Rs.195.7 crore, up by 71%. PAT after forex was at Rs 166.6 crore as against Rs.16.4 crore in Q1FY09. However, the PAT before Forex was at Rs.109 crore, up 55%.
During the quarter, the company repurchased and cancelled FCCBs of face value of USD 1.8 million. In Q1 FY 2009-10, it had 8 ANDA filings in USA, taking the total cumulative filings to155. It also had 13 Dossier filings in Europe in Q1 FY 2009-10 , taking the total cumulative filings to 677.
In August, the company acquired Hyderabad-based Trident Life Sciences for about Rs.134 crore. It will fund the deal through internal cash flow and will repay the debt on Trident Life Sciences' books in the next six to nine months. This acquisition will give Aurobindo an opportunity to enter the injectables business as Trident is building a liquid injectables facility in Medak, Hyderabad, scheduled to go on stream in April 2011.
Since the last few days, Aurobindo has acquired quite a few approvals for its drugs from USFDA as well as Switzerland. And that is precisely why the stock price has remained up and is expected to remain firm in the coming days too. A strong company, it’s a long term stock for portfolio building.
No comments:
Post a Comment